Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity
Conclusions This review of the 30-year clinical experience with Influvac® found that the overall benefit-to-risk ratio is positive for all age groups from 6months upwards. The currently available evidence from the many clinical trials that have been performed confirms that Influvac® remains an effective and safe vaccine for preventing seasonal influenza. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Rotavirus gastroenteritis in Latin America: A hospital-based study in children under 3years of age
This study confirms the high disease burden of rotavirus gastroenteritis among children in Latin America, which might be reduced by the use of effective vaccines. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Conclusions The candidate TB vaccine, MVA85A has been safely administered to over 100 healthy adults in the UK. Intradermal vaccination with MVA85A induced a transient, superficial reaction local to the injection site and mild short-lived viral symptoms. The local and systemic AE profile of MVA85A vaccination was comparable to published data of other intradermal vaccines and live viral vaccines respectively. Local reaction sizes and body temperature measurements did not correlate with the adaptive cellular immune response to MVA85A. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173
Conclusions Randomized controlled trials such as CTN 173, with well-defined surrogate endpoints and frequent immunologic and virologic monitoring, are necessary to streamline the approach to effective vaccine discovery and to ensure patient safety. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience
Publication date: 2012 Source:Trials in Vaccinology, Volume 1 Author(s): Irene Perez Schael , Miguel O’Ryan , Xavier Sáez-Llorens , Alexandre C. Linhares , F.R. Velázquez , Romulo E. Colindres , Thomas Breuer , Eduardo Ortega-Barria Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) among infants and young children worldwide, accounting for 453,000 deaths in children aged <5years. In Latin America rotavirus causes an estimated 15,000 deaths annually and accounts for 20–70% of acute gastroenteritis cases requiring hospitalization. This results in an estimated annual cost of approxima...
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Rotavirus serotype distribution in northern Brazil trends over a 27 year period pre and post national vaccine introduction
Publication date: 2012 Source:Trials in Vaccinology, Volume 1 Author(s): Alessilva Oliveira , Joana D’Arc P. Mascarenhas , Luana S. Soares , Sylvia F.S. Guerra , Yvone B. Gabbay , Nervo Sánchez , Romulo E. Colindres , Maria Cleonice A. Justino , Alexandre C. Linhares In Brazil, a rotavirus vaccine was included in the public sector in March 2006. In order to identify a possible effect of vaccination on rotavirus strains we evaluated the distribution of serotypes/genotypes in northern Brazil during pre (1981–2005) and early post (2006–2008) national rotavirus vaccine introduction periods. Of 1286 rotaviru...
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Welcome Editorial to Trials in Vaccinology
Publication date: 2012 Source:Trials in Vaccinology, Volume 1 Author(s): Ray Spier (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Publisher’s Note – Launching Trials in Vaccinology
Publication date: 2012 Source:Trials in Vaccinology, Volume 1 (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
A neonatal oral Mycobacterium tuberculosis-SIV prime/intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques
Publication date: 2013 Source:Trials in Vaccinology, Volume 2 Author(s): Kara Jensen , Myra Grace dela Pena , Robert L. Wilson , Uma Devi K. Ranganathan , William R. Jacobs Jr. , Glenn Fennelly , Michelle Larsen , Koen K.A. Van Rompay , Pamela A. Kozlowski , Kristina Abel Mother-to-child-transmission of HIV by breast-feeding remains a major obstacle in the eradication of HIV infection. Compared to adults, HIV-infected infants have more rapid disease and show higher susceptibility to co-infections like tuberculosis (TB). Although the Bacille Calmette–Guérin vaccine can be administered at birth to protect ag...
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Effectiveness, tolerability and patient satisfaction of paediatric live-attenuated influenza immunization (LAIV) in routine-care in Germany: A case-control-study
Conclusion In routine administration in Germany, LAIV was highly effective and well-tolerated, resulting in good patient satisfaction. Nasal LAIV offers a suitable way to increase paediatric influenza immunization coverage. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65years and over in the North East of England, April 2006–July 2012
Publication date: 2013 Source:Trials in Vaccinology, Volume 2 Author(s): L.B. Wright , G.J. Hughes , K.E. Chapman , R. Gorton , D. Wilson The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged ⩾65years in the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged ⩾65years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using a stratified analysis. VE for persons aged ⩾65years was 28.5% (95% confidenc...
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle
This study suggests that subject to confirmation of non-inferiority in an appropriately powered study, the Stratis DSJI is a viable alternative strategy for the administration of seasonal influenza vaccines with particular appeal for individuals with needle phobia. Australia New Zealand Clinical Trials Register: ACTRN12612000709842. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance
Conclusion Our findings confirm that B cell malignancies and disorders among elderly patients are associated with suboptimal responses to pneumococcal vaccination. Single-dose PCV7 was not shown to be superior to PPV. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Hospital-based surveillance study of rotavirus gastroenteritis in children under 5years of age in Lebanon
Conclusion RVGE hospitalizations are prevalent in children under 5years of age in Lebanon. This baseline data might be useful for decision makers when initiating measures, such as vaccination, to prevent the disease. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
Implementation of the quadrivalent vaccine against HPV in the Municipality of Campos dos Goytacazes, Brazil – A combination of strategies to increase immunization coverage and early reduction of genital warts
Conclusion A hybrid strategy for HPV proved to be effective in vaccinating adolescents in this municipality. HPV vaccine was safe and effective in reducing genital warts, as demonstrated by international studies. (Source: Trials in Vaccinology)
Source: Trials in Vaccinology - October 12, 2014 Category: Infectious Diseases Source Type: research
